Citi Downgrades Bristol-Myers Squibb Co. (BMY) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil prices steady as investors weigh US-Iran war escalation
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
Bristol-Myers Squibb (BMY) Pressured on Market Open, Down 6.6%
October 22, 2018 9:31 AM EDTBristol-Myers Squibb (NYSE: BMY) Pressured on Market Open, Down 6.6%
... MoreBristol-Myers Squibb (BMY) Reports Data from Phase 3 CheckMate -067 Clinical Trial for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab)
October 22, 2018 6:00 AM EDTBristol-Myers Squibb Company (NYSE: BMY) today announced four-year data from the Phase 3 CheckMate -067 clinical trial the longest follow-up to date which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma. With a minimum follow-up of 48 months,... More
